Clinical observation of Shouhui tongbian capsule combined with linaclotide in the treatment of constipation-predominant irritable bowel syndrome

HAO Manxia; WANG Shengwen; YAO Lishan

doi:10.6039/j.issn.1001-0408.2025.22.13

您当前的位置：

首页 >

文章列表页 >

Clinical observation of Shouhui tongbian capsule combined with linaclotide in the treatment of constipation-predominant irritable bowel syndrome

更新时间：2025-11-25

- Clinical observation of Shouhui tongbian capsule combined with linaclotide in the treatment of constipation-predominant irritable bowel syndrome
- ZHONGGUO YAOFANG Vol. 36, Issue 22, Pages: 2828-2832(2025)
- 作者机构：
  
  1.南阳市第一人民医院中药科，河南南阳　473000
  2.南阳市第一人民医院肛肠科，河南南阳　473000
  3.南阳市中心医院中药药学部，河南南阳　473000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.22.13
  CLC： R969.4;R574.6
- Received：08 July 2025，
  
  Revised：2025-10-10，
  
  Accepted：13 October 2025，
  
  Published：30 November 2025
- 稿件说明：
移动端阅览
郝满霞,王胜文,姚立山.首荟通便胶囊联合利那洛肽治疗便秘型肠易激综合征的临床观察 ^Δ[J].中国药房,2025,36(22):2828-2832.

HAO Manxia,WANG Shengwen,YAO Lishan.Clinical observation of Shouhui tongbian capsule combined with linaclotide in the treatment of constipation-predominant irritable bowel syndrome[J].ZHONGGUO YAOFANG,2025,36(22):2828-2832.
郝满霞,王胜文,姚立山.首荟通便胶囊联合利那洛肽治疗便秘型肠易激综合征的临床观察 ^Δ[J].中国药房,2025,36(22):2828-2832. DOI： 10.6039/j.issn.1001-0408.2025.22.13.

HAO Manxia,WANG Shengwen,YAO Lishan.Clinical observation of Shouhui tongbian capsule combined with linaclotide in the treatment of constipation-predominant irritable bowel syndrome[J].ZHONGGUO YAOFANG,2025,36(22):2828-2832. DOI： 10.6039/j.issn.1001-0408.2025.22.13.

摘要

目的

探讨首荟通便胶囊联合利那洛肽治疗便秘型肠易激综合征（IBS-C）的疗效和安全性。

方法

选择2022年3月至2024年2月南阳市第一人民医院收治的97例IBS-C患者，按随机数字表法分为对照组（

＝46）和观察组（

＝51）。在常规治疗的基础上，对照组患者口服利那洛肽胶囊，观察组患者口服利那洛肽胶囊和首荟通便胶囊，两组患者疗程均为4周。比较两组患者的临床疗效，治疗前后的IBS症状严重程度量表（IBS-SSS）评分、排便次数、Bristol粪便性状量表（BSFS）评分、IBS生活质量量表（IBS-QOL）评分、胃肠激素水平、肛管直肠动力学指标，以及不良反应发生情况。

结果

对照组有2例、观察组有3例患者因不良反应脱落。观察组患者的有效率显著高于对照组（87.50% vs. 68.18%，

＜0.05）。与治疗前比较，治疗后两组患者的排便次数、BSFS评分、血清P物质和胃动素水平均显著升高，IBS-SSS评分、IBS-QOL评分、血清血管活性肠肽水平、肛管直肠压力差、直肠顺应性、直肠感觉阈值、排便阈值均显著降低（

＜0.05），且观察组显著优于对照组（直肠感觉阈值、排便阈值除外）（

＜0.05）。两组患者的不良反应总发生率比较，差异无统计学意义（

＞0.05）。

结论

相比于单用利那洛肽，首荟通便胶囊联合利那洛肽可改善IBS-C患者的胃肠激素功能及肛管直肠动力学，减轻临床症状，提高生活质量，且安全性较好。

Abstract

OBJECTIVE

To investigate the clinical efficacy and safety of Shouhui tongbian capsule combined with linaclotide in the treatment of constipation-predominant irritable bowel syndrome （IBS-C）.

METHODS

A total of 97 IBS-C patients admitted to Nanyang First People’s Hospital between March 2022 and February 2024 were enrolled. Using a random number table method， patients were divided into control group （

＝46） and observation group （

＝51）. On the basis of routine treatment， the control group was given Linaclotide capsules orally， while the observation group received Linaclotide capsules combined with Shouhui tongbian capsule orally. The treatment course for both groups was 4 weeks. Clinical efficacy， Irritable Bowel Syndrome Severity Scale （IBS-SSS）， stool frequency， Bristol Stool Form Scale （BSFS）， Irritable Bowel Syndrome Quality of Life Questionnaire （IBS-QOL） score， gastrointestinal hormone levels， anorectal manometry parameters， and the occurrence of adverse reactions were compared between the two groups.

RESULTS

Two patients in the control group and three patients in the observation group dropped out due to adverse reactions. The effective rate in the observation group （87.50%） was significantly higher than that in the control group （68.18%）（

＜0.05）. Compared with pre-treatment， both groups showed significant increase in post-treatment stool frequency， BSFS score， serum substance P， and motilin levels. Conversely， IBS-SSS scores， IBS-QOL scores， serum vasoactive intestinal peptide levels， anal-rectal pressure difference， rectal compliance， rectal sensation threshold， and defecation threshold were significantly reduced （

＜0.05）. The observation group demonstrated superior outcomes to the control group （excluding rectal sensation and defecation thresholds，

＜0.05）. No significant difference in the incidence of adverse reactions was observed between the tw

o groups （

＞0.05）.

CONCLUSIONS

Compared with linaclotide monotherapy， Shouhui tongbian capsule combined with linaclotide improves gastrointestinal hormone function and anorectal manometry parameters in IBS-C patients， alleviates clinical symptoms， improves quality of life， and exhibits favorable safety.

关键词

Keywords

references

DI ROSA C ， ALTOMARE A ， TERRIGNO V ， et al . Constipation-predominant irritable bowel syndrome（IBS-C）：effects of different nutritional patterns on intestinal dysbiosis and symptoms [J ] . Nutrients ， 2023 ， 15 （ 7 ）： 1647 .

高炼，黄晓明，吴清明 . 肠易激综合征治疗与预防的研究进展 [J ] . 中国全科医学， 2022 ， 25 （ 9 ）： 1148 - 1154 .

CHIARIONI G ， POPA S L ， ISMAIEL A ， et al . Herbal remedies for constipation-predominant irritable bowel syndrome：a systematic review of randomized controlled trials [J ] . Nutrients ， 2023 ， 15 （ 19 ）： 4216 .

WECHSLER E V ， SHAH E D . Diarrhea-predominant and constipation-predominant irritable bowel syndrome：current prescription drug treatment options [J ] . Drugs ， 2021 ， 81 （ 17 ）： 1953 - 1968 .

冷玉静，方胡凤，杨浩，等 . 利那洛肽治疗便秘型肠易激综合征的快速卫生技术评估 [J ] . 中国药房， 2023 ， 34 （ 18 ）： 2263 - 2268 .

中华医学会消化病学分会胃肠功能性疾病协作组，中华医学会消化病学分会胃肠动力学组 . 2020年中国肠易激综合征专家共识意见 [J ] . 中华消化杂志， 2020 ， 40 （ 12 ）： 803 - 818 .

梁红宝，李蕊，姚景春，等 . 基于网络药理学和分子对接方法研究首荟通便胶囊治疗便秘的作用机制 [J ] . 中国中药杂志， 2021 ， 46 （ 3 ）： 511 - 519 .

PAZHOUH H K ， HOSSEINI S M A ， TAGHIPOUR A ， et al . Anti-irritable bowel syndrome syrup improves constipation-predominant irritable bowel syndrome：a randomized，placebo-controlled trial [J ] . Chin J Integr Med ， 2020 ， 26 （ 10 ）： 729 - 735 .

FRANCIS C Y ， MORRIS J ， WHORWELL P J . The irritable bowel severity scoring system：a simple method of monitoring irritable bowel syndrome and its progress [J ] . Aliment Pharmacol Ther ， 1997 ， 11 （ 2 ）： 395 - 402 .

BLAKE M R ， RAKER J M ， WHELAN K . Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome [J ] . Aliment Pharmacol Ther ， 2016 ， 44 （ 7 ）： 693 - 703 .

FORD A C ， LACY B E ， TALLEY N J . Irritable bowel syndrome [J ] . N Engl J Med ， 2017 ， 376 （ 26 ）： 2566 - 2578 .

袁耀宗 . 便秘型肠易激综合征诊疗进展专家会议纪要 [J ] . 中华消化杂志， 2019 ， 39 （ 3 ）： 197 - 198 .

周慧芬，徐安妗，祝方良 . 中医治疗便秘型肠易激综合征的临床观察 [J ] . 中华中医药学刊， 2014 ， 32 （ 3 ）： 683 - 685 .

龚立平，郭欣，黄娜娜，等 . 首荟通便胶囊治疗功能性便秘的研究进展 [J ] . 中草药， 2022 ， 53 （ 18 ）： 5899 - 5907 .

王天园，陈朝霞，王彦博，等 . 首荟通便胶囊治疗慢性便秘的疗效可能优于西医常规治疗：基于随机对照试验的系统评价 [J ] . 中国全科医学， 2021 ， 24 （ 23 ）： 2972 - 2977 .

周佳宝，周锦花 . 首荟通便胶囊治疗老年功能性便秘的疗效观察 [J ] . 中国全科医学， 2019 ， 22 （增刊2 ）： 149 - 151 .

CUI L ， HUA Y Z ， ZOU S T ， et al . Combination of fenchone and sodium hyaluronate ameliorated constipation-predominant irritable bowel syndrome and underlying mechanisms [J ] . Chem Biol Drug Des ， 2024 ， 103 （ 1 ）： e14397 .

鲍聚喜，冯作鹏，张光鑫，等 . 便秘型肠易激综合征患者肛门直肠感觉及动力学变化的临床研究 [J ] . 中国普外基础与临床杂志， 2019 ， 26 （ 1 ）： 38 - 41 .

LIU J ， DAI Q ， QU T ， et al . Ameliorating effects of transcutaneous auricular vagus nerve stimulation on a mouse model of constipation-predominant irritable bowel syndrome [J ] . Neurobiol Dis ， 2024 ， 193 ： 106440 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety comparison of dupilumab versus thalidomide in the treatment of refractory prurigo nodularis in adults

Advances in the clinical application and safety of bispecific antibodies for cancer therapy

Efficacy and safety of ruxolitinib in the treatment of myelofibrosis

Clinical observation of doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children under 8 years of age

Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer

Related Author

ZHANG Jianbo

HU Lei

HUANG Hegui

LIU Yangcong

WANG Xiaoxian

LIN Mengmeng

LIN Xu

WANG Yixuan

Related Institution

Dept. of Pharmacy， Wuhan First Hospital

Dept. of Clinical Pharmacy， Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province， Affiliated Hangzhou First People’s Hospital， School of Medicine， Westlake University

Dept. of Thoracic Surgery， the First Affiliated Hospital， Zhejiang University School of Medicine

School of Pharmaceutical Sciences， Zhejiang Chinese Medical University

School of Pharmaceutical Sciences， Wenzhou Medical University

⁰